ARTICLE | Deals
Abbvie seeks molecular glue degraders from Neomorph
Also in BioCentury’s Deals Report, Novo licenses BACH1 inhibitor from Immvention, Arrivent-Lepu in ADC deal, and Sage rejects Biogen’s bid
January 28, 2025 1:03 AM UTC
Deal activity has remained slow following the J.P. Morgan bonanza, with the past week bringing just three notable partnerships.
Abbvie Inc. (NYSE:ABBV) became the third partner to seek molecular glue degraders from Neomorph Inc., following the biotech’s deals with Biogen Inc. (NASDAQ:BIIB) and Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) last year. ...